步长制药：泸州步长拟与MEDISPEC签署《独家供应协议》

Core Viewpoint - The company, Buchang Pharma, announced that its subsidiary, Luzhou Buchang, plans to sign an exclusive supply agreement with Malaysian company MEDISPEC for the registration, promotion, distribution, and sales of injectable Efparepoetin alfa in a designated region [1] Group 1 - Luzhou Buchang will authorize MEDISPEC as the exclusive agent in the target area for the product [1] - Injectable Efparepoetin alfa is a recombinant fusion protein composed of erythropoietin (EPO) and human immunoglobulin G2 (IgG2) Fc fragment [1] - There are currently no similar products approved for sale in the domestic market [1]